Side-effect concerns prompt changes to Transgene's hep C vaccine study
This article was originally published in Scrip
Executive Summary
Three serious adverse events in the treatment arm of a large Phase II trial of Transgene's investigational hepatitis C therapeutic vaccine TG4040 have prompted a protocol change for the study and fears they may lead to delays to the product's development programme.